



MAV+ Ghana

Last updated: March 2025

Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (MAV+) is a comprehensive support package tackling barriers to manufacturing and access to health products and technologies in Africa. MAV+ is tightly aligned with African strategies and is supported by a broad and inclusive consortium of European actors.

Ghana is well-positioned to be a regional and continental hub for vaccines and medicines manufacturing. MAV+ supports Ghana in increasing its regional impact by enhancing manufacturing capacity and promoting technology transfer, while also strengthening the Ghana FDA's role as a Regional Center of Regulatory Excellence (RCORE) in vaccine regulatory oversight.

Key MAV+ collaborations and activities

Strengthening Ghana Food and Drugs Authority (FDA) as Regional Center of Regulatory Excellence (RCORE) in vaccine regulatory oversight

MAV+ provides support to Ghana FDA through a comprehensive program aimed at strengthening vaccine regulation for effective vaccine oversight and production. Ghana FDA inspectors participated in intensive vaccine Good Manufacturing Practices (GMP) training in the Netherlands to ensure locally produced vaccines meet international safety and quality standards.

The Special Measure 2023 will support Ghana FDA by covering operational costs for RCORE training, enhance Ghana FDA's role in regulatory harmonization efforts and facilitate mentoring, peer learning and technical exchanges with other national regulatory authorities in the region.

Ghana plays active role in multi-country partnerships on regulation. Highlights include collaborations on quality assurance and quality management to combat Antimicrobial Resistance (AMR), market authorisation, batch-testing and vaccine release.

Ghana

**€48.99
million**

7 projects*

*excludes multi-country projects

Key regulatory moments

In 2020, Ghana FDA achieved WHO Maturity Level 3 for medicines and vaccines (non-producing). In 2022, the Drugs Laboratory achieved WHO Maturity Level 4 and was awarded WHO-Prequalified Quality Control Laboratory status, making it the first laboratory in West/Central Africa to achieve this status.



Boosting local manufacturing and offtake mechanisms

In the framework of the Ghanaian 10-year roadmap for vaccine development and manufacturing, Team Europe supports DEK Vaccines Limited, a consortium of three Ghanaian pharmaceutical companies (Danadams, Ernest Chemists and Kinapharma) that was selected to produce vaccines for Ghana, the ECOWAS region and Africa to shore up the continent's capability to produce vaccines locally. DEK is establishing a fill and finish facility that will produce approximately 600 million doses of vaccines annually, including the oral cholera vaccine, which is anticipated to be available in 2025.

Supporting R&D and promoting technology transfer

MAV+ will facilitate networking and building of strong international partnerships for technology transfer according to the WHO guidelines on technology transfer in pharmaceutical manufacturing including support for licensing and intellectual property management.

Team Europe funders

MAV+ actions in Ghana are primarily funded by the European Commission and Germany. Germany also funds activities in Ghana that are part of multi-country projects.

Partners

National partners include DEK Vaccines Limited, Ghana Food and Drugs Authority (FDA), Kwame Nkrumah University of Science and Technology (KNUST), Ministry of Trade and Industry (MoTI), Presidential Vaccine Manufacturing Committee (VMC), NVI (National Vaccine Institute), as well as SMEs and research institutions. Ghana FDA is also a key partner for multi-country projects.

Additional Team Europe and international stakeholders

Stakeholders for national projects include GIZ; stakeholders for multi-country projects include DEG (German Investment Corporation), Paul-Ehrlich-Institut (PEI), the German Federal Institute for Drugs and Medical Devices and WHO.

